Nurix Therapeutics (NRIX) Capital Expenditures (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Capital Expenditures for 8 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Capital Expenditures rose 153.27% year-over-year to $1.3 million; the TTM figure through May 2026 stood at $3.1 million (up 288.65% YoY), while the FY2025 annual figure was $1.2 million, down 28.0% from the prior year.
• Capital Expenditures retreated to $1.3 million in Q2 2026 per NRIX's latest filing, from $1.7 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $7.0 million in Q3 2022 and bottomed at -$5.5 million in Q4 2024.
• Historically, Capital Expenditures has averaged $1.0 million across 5 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2022 — Capital Expenditures jumped 311.86% — and 2025, when it tumbled 323.12%.
• Nurix Therapeutics' Capital Expenditures stood at $2.6 million in 2022, then slumped by 302.11% to -$5.2 million in 2023, then retreated by 6.58% to -$5.5 million in 2024, then soared by 83.04% to -$937000.0 in 2025, then jumped by 236.61% to $1.3 million in 2026.
• Business Quant data shows NRIX's Capital Expenditures at $1.3 million in Q2 2026, $1.7 million in Q1 2026, and -$937000.0 in Q4 2025.